Skip to main content

Advertisement

SpringerLink
Log in

Microwave ablation plus chemotherapy improved progression-free survival of advanced non-small cell lung cancer compared to chemotherapy alone

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The aim of the study was to determine survival benefit of the microwave ablation (MWA)/chemotherapy combination compared with chemotherapy alone. Patients with untreated, stage IIIB or IV NSCLC and at least one additional measurable site other than the ablative site were enrolled. They were divided into MWA/chemotherapy group and chemotherapy group. The primary endpoint was progression-free survival (PFS); secondary endpoints included response, time to local progression (TTLP), overall survival (OS), and adverse events (AEs). Forty-six and twenty-eight patients were enrolled in the MWA/chemotherapy group and chemotherapy group, respectively. Complete ablation was observed in 84.8 % patients in the MWA/chemotherapy group. Median TTLP was 27.0 months. Objective response rate and disease control rate in MWA/chemotherapy group were 21.7 and 76.1 %, and in the chemotherapy group were 32.1 % (p = 0.320) and 75.0 % (p = 0.916), respectively. MWA/chemotherapy combination prolonged PFS [MWA/chemotherapy group 10.9 (95 % CI 5.1–16.7) ms vs. chemotherapy group 4.8 (95 % CI 3.9–5.8) ms, p = 0.001] and tended to improve OS [MWA/chemotherapy group 23.9 (95 % CI 15.2–32.6) ms vs. chemotherapy group 17.3 (95 % CI 15.2–19.3) ms, p = 0.140]. Multivariate analyses showed that MWA was an independent prognostic factor of PFS and primary tumor size was an independent prognostic factor of OS. AEs of MWA were observed in 67.4 % patients. Chemotherapy-associated AEs were observed in 39.1 and 53.6 % of patients in the MWA/chemotherapy and chemotherapy group, respectively. MWA/chemotherapy combination improved PFS of advanced NSCLC compared to chemotherapy alone, and the combination did not increase the adverse events of chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Chen W, Zheng R, Zhang S, et al. Annual report on status of cancer in China, 2010. Chin J Cancer Res. 2014;26(1):48–58.

    PubMed Central  PubMed  Google Scholar 

  2. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–8.

    Article  CAS  PubMed  Google Scholar 

  3. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–51.

    Article  CAS  PubMed  Google Scholar 

  4. Duisters C, Beurskens H, Nijsten S, et al. Palliative chest irradiation in sitting position in patients with bulky advanced lung cancer. Radiother Oncol. 2006;79(3):285–7.

    Article  PubMed  Google Scholar 

  5. Zhang S, Zheng Y, Yu P, et al. The combined treatment of CT-guided percutaneous 125I seed implantation and chemotherapy for non-small-cell lung cancer. J Cancer Res Clin Oncol. 2011;137(12):1813–22.

    Article  CAS  PubMed  Google Scholar 

  6. Li X, Zhao M, Wang J, et al. Percutaneous CT-guided radiofrequency ablation as supplemental therapy after systemic chemotherapy for selected advanced non-small cell lung cancer. AJR Am J Roentgenol. 2013;201(6):1362–7.

    Article  PubMed  Google Scholar 

  7. Liu H, Steinke K. High-powered percutaneous microwave ablation of stage I medically inoperable non-small cell lung cancer: a preliminary study. J Med Imaging Radiat Oncol. 2013;57(4):466–74.

    Article  CAS  PubMed  Google Scholar 

  8. Lu Q, Cao W, Huang L, et al. CT-guided percutaneous microwave ablation of pulmonary malignancies: results in 69 cases. World J Surg Oncol. 2012;10:80.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Carrafiello G, Mangini M, De Bernardi I, et al. Microwave ablation therapy for treating primary and secondary lung tumours: technical note. Radiol Med. 2010;115(6):962–74.

    Article  CAS  PubMed  Google Scholar 

  10. Jones C, Badger SA, Ellis G, et al. The role of microwave ablation in the management of hepatic colorectal metastases. Surgeon. 2011;9:33–7.

    Article  CAS  PubMed  Google Scholar 

  11. Liang P, Wang Y. Microwave ablation of hepatocellular carcinoma. Oncology. 2007;72(S):124–31.

    Article  PubMed  Google Scholar 

  12. Wei Z, Ye X, Yang X, et al. Microwave ablation in combination with chemotherapy in the treatment of advanced non-small cell lung cancer. Cardiovasc Intervent Radiol. 2014;. doi:10.1007/s00270-014-0895-0.

    PubMed  Google Scholar 

  13. Watanabe H, Okada M, Kaji Y, et al. New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1). Gan To Kagaku Ryoho. 2009;36:2495–501.

    PubMed  Google Scholar 

  14. Ye X, Fan W. Expert consensus for thermal ablation of primary and metastatic lung tumors. Zhongguo Fei Ai Za Zhi. 2014;17(4):294–301.

    PubMed  Google Scholar 

  15. Lee H, Jin GY, Han YM, et al. Comparison of survival rate in primary non-small-cell lung cancer among elderly patients treated with radiofrequency ablation, surgery, or chemotherapy. Cardiovasc Intervent Radiol. 2012;35:343–50.

    Article  PubMed  Google Scholar 

  16. Wang SB, Chen JH, Cao W, et al. The observation of the clinical effect for combination therapy of RFA with GP on advanced stage lung cancer. Chin J Clin Oncol. 2005;32(11):628–30.

    Google Scholar 

  17. Zhang HM, Feng WJ, Zhou L, et al. Addition of cluster electrode radiofrequency ablation (RFA) to paclitaxal plus carboplatin(PC) for advanced NSCLC: clinical observation. Eval Anal Drug-use Hosp China. 2008;8(7):540–2.

    CAS  Google Scholar 

  18. Clasen S, Krober SM, Kosan B, et al. Pathomorphologic evaluation of pulmonary radiofrequency ablation: proof of cell death is characterized by DNA fragmentation and apoptotic bodies. Cancer. 2008;113:3121–9.

    Article  PubMed  Google Scholar 

  19. Jaskolka JD, Kachura JR, Hwang DM, et al. Pathologic assessment of radiofrequency ablation of pulmonary metastases. J Vasc Interv Radiol. 2010;21:1689–96.

    Article  PubMed  Google Scholar 

  20. Ryan ER, Sofocleous CT, Schoder H, et al. Split-dose technique for FDG PET/CT-guided percutaneous ablation: a method to facilitate lesion targeting and to provide immediate assessment of treatment effectiveness. Radiology. 2013;268:288–95.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Duan YQ, Gao YY, Ni XX, et al. Changes in peripheral lymphocyte subsets in patients after partial microwave ablation of the spleen for secondary splenomegaly and hypersplenism: a preliminary study. Int J Hyperthermia. 2007;23(5):467–72.

    Article  CAS  PubMed  Google Scholar 

  22. Zhou P, Liang P, Dong B, et al. Phase I clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma. Cancer Biol Ther. 2011;11(5):450–6.

    Article  CAS  PubMed  Google Scholar 

  23. Goldberg SN, Saldinger PF, Gazelle GS, et al. Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intratumoral doxorubicin injection in a rat breast tumor model. Radiology. 2001;220(2):420–7.

    Article  CAS  PubMed  Google Scholar 

  24. Goldberg SN, Girnan GD, Lukyanov AN, et al. Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model. Radiology. 2002;222(3):797–804.

    Article  PubMed  Google Scholar 

  25. Goldberg SN, Kamel IR, Kruskal JB, et al. Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy. AJR Am J Roentgenol. 2002;179(1):93–101.

    Article  PubMed  Google Scholar 

  26. Solazzo SA, Ahmed M, Schor-Bardach R, et al. Liposomal doxorubicin increases radiofrequency ablation-induced tumor destruction by increasing cellular oxidative and nitrative stress and accelerating apoptotic pathways. Radiology. 2010;255(1):62–74.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Kong G, Anyarambhatla G, Petros WP, et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res. 2000;60(24):6950–7.

    CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwuweiqi Road, Jinan, 250021, Shandong Province, China

    Zhigang Wei, Xin Ye, Xia Yang, Guanghui Huang, Wenhong Li, Jiao Wang & Xiaoying Han

Authors
  1. Zhigang Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xin Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xia Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guanghui Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wenhong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jiao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiaoying Han
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xin Ye.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wei, Z., Ye, X., Yang, X. et al. Microwave ablation plus chemotherapy improved progression-free survival of advanced non-small cell lung cancer compared to chemotherapy alone. Med Oncol 32, 13 (2015). https://doi.org/10.1007/s12032-014-0464-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0464-z

Keywords

Search

Navigation